The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer

The treatment of metastatic non-small cell lung cancer (NSCLC) has undergone a paradigm shift over the last decade. Better molecular characterization of the disease has led to the rapid improvement of personalized medicine and the prompt delivery of targeted therapies to patients with NSCLC. The dis...

Full description

Bibliographic Details
Main Authors:	Valerio Gristina, Maria La Mantia, Federica Iacono, Antonio Galvano, Antonio Russo, Viviana Bazan
Format:	Article
Language:	English
Published:	MDPI AG 2020-12-01
Series:	Pharmaceuticals
Subjects:	non-small cell lung cancer (NSCLC) tyrosine kinase inhibitors (TKIs) ALK inhibitors crizotinib ceritinib alectinib
Online Access:	https://www.mdpi.com/1424-8247/13/12/474

Similar Items

Role and targeting of anaplastic lymphoma kinase in cancer
by: Carminia Maria Della Corte, et al.
Published: (2018-02-01)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of <i>ALK</i>-Rearranged NSCLC: <i>ALK</i>- and <i>BRAF</i>-Mutations Followed by Epithelial-Mesenchymal Transition
by: Edyta M. Urbanska, et al.
Published: (2020-04-01)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
by: Qian Zhu, et al.
Published: (2017-06-01)

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
by: Hideko Isozaki, et al.
Published: (2015-04-01)

Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials
by: Tung Hoang, et al.
Published: (2020-02-01)

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China
by: Zihua Zou, et al.
Published: (2022-01-01)

From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting
by: Lee AT, et al.
Published: (2023-06-01)

Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer
by: Cheng-Hao Chuang, et al.
Published: (2021-04-01)

Focus on Alectinib and Competitor Compounds for Second Line Therapy in ALK Rearranged NSCLC
by: Samuel J Klempner, et al.
Published: (2016-11-01)

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
by: Ryohei Katayama, et al.
Published: (2016-01-01)

New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib
by: Rothschild SI
Published: (2016-05-01)

Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
by: Jain RK, et al.
Published: (2017-10-01)

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
by: Santarpia M, et al.
Published: (2017-07-01)

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
by: Gianluca Spitaleri, et al.
Published: (2023-05-01)

Drug interactions between ALK inhibitors and warfarin with concurrent use of bucolome: a case report
by: Takashi Kato, et al.
Published: (2023-05-01)

Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer
by: Savvas Papageorgiou, et al.
Published: (2022-07-01)

Thyroid dysfunction induced by alectinib in a patient with a non-small cell lung cancer
by: L. Plaza-Enriquez, et al.
Published: (2022-06-01)

Clinical characteristics and risk factors of drug‐induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis
by: Ken Koshikawa, et al.
Published: (2020-06-01)

ALK Rearrangement–Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report
by: Kai Ou, et al.
Published: (2021-09-01)

Targeted therapy of brain metastases in patients with ALK-positive non-small cell lung cancer: A review
by: Dina D. Sakaeva, et al.
Published: (2021-12-01)

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis
by: Ibiayi Dagogo-Jack, MD, et al.
Published: (2023-08-01)

A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC
by: Josephina Sampson, et al.
Published: (2022-02-01)

Efficacy of crizotinib therapy for a patient with non-small cell lung cancer with ALK gene rearrangement – case report and review of current therapeutic options
by: Julia Barbara Bargieł, et al.
Published: (2021-09-01)

A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib
by: Yuki Matsumura, et al.
Published: (2021-08-01)

The potential role of HGF-MET signaling and autophagy in the war of Alectinib versus Crizotinib against ALK-positive NSCLC
by: Xing Huang
Published: (2018-02-01)

Clinical Profile, Practice Pattern, and Outcomes With First-Line Therapy in ALK-Positive Lung Cancer: Real-World Data From Resource-Constrained Settings
by: Akhil Kapoor, MD, DM, et al.
Published: (2023-01-01)

Evaluation of Efficacy of ALK Inhibitors According to Body Mass Index in ALK Rearranged NSCLC Patients—A Retrospective Observational Study
by: Marco Siringo, et al.
Published: (2023-06-01)

Current approaches to therapy of ALK-positive non-small cell lung cancer
by: К. К. Laktionov, et al.
Published: (2021-06-01)

First-Line Treatment of ALK-Positive NSCLC
by: Hasna Bouchaab
Published: (2019-11-01)

Clinical case of prolonged use of alectinib in the treatment of ALK-positive NSCLC
by: S. G. Bagrova, et al.
Published: (2019-12-01)

Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers
by: Abdulraheem Alshareef
Published: (2017-10-01)

Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report
by: Kunyan Sun, et al.
Published: (2021-06-01)

Case Report: Patient With Lung Adenocarcinoma With ALK-HLA-DRB1 Rearrangement Shows Impressive Progression-Free Survival After Sequential Crizotinib and Ceritinib Treatment
by: Peng Gao, et al.
Published: (2022-02-01)

An insight into lung cancer: a comprehensive review exploring ALK TKI and mechanisms of resistance
by: Adela Patcas, et al.
Published: (2022-02-01)

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
by: Yue Pan, et al.
Published: (2021-10-01)

Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer
by: Emilio Francesco Giunta, et al.
Published: (2022-06-01)

Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond
by: Nina Prokoph, et al.
Published: (2018-03-01)

Hemolytic anemia caused by alectinib, an Anaplastic Lymphoma Kinase (ALK) inhibitor: A case report
by: Robina Aerts, et al.
Published: (2022-09-01)

Spoilt for choice: different immunosuppressive potential of anaplastic lymphoma kinase inhibitors for non small cell lung cancer
by: Annkristin Heine, et al.
Published: (2023-09-01)

Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib
by: Justin M. Cheung, MD, et al.
Published: (2024-03-01)